Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 3
2009 12
2010 2
2011 4
2012 3
2013 3
2014 1
2015 1
2016 2
2019 4
2020 6
2021 2
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Feagan BG, et al. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. N Engl J Med. 2013. PMID: 23964932 Free article. Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Free article. Clinical Trial.
RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy.
Ergenç İ, Kani HT, Karabacak M, Cömert Özer E, Mehdiyev S, Jafarov F, Abacar KY, Kutluğ Ağaçkıran S, Sevik G, Aslan R, Alibaz Öner F, İnanç N, Atagündüz MP, Seçkin D, Özen Alahdab Y, Ergun T, Direskeneli H, Atuğ Ö. Ergenç İ, et al. Among authors: atug o. Turk J Gastroenterol. 2023 Mar;34(3):310. doi: 10.5152/tjg.2023.237002. Turk J Gastroenterol. 2023. PMID: 36919837 Free PMC article. No abstract available.
Incidence rate of anemia in inflammatory bowel diseases.
Atuğ Ö, Kani HT, Banzragch M, İmeryüz N, Akın H. Atuğ Ö, et al. Turk J Gastroenterol. 2016 Mar;27(2):143-8. doi: 10.5152/tjg.2016.16011. Turk J Gastroenterol. 2016. PMID: 27015619 Free article.
Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B.
Ergenç İ, Kani HT, Karabacak M, Cömert Özer E, Mehdiyev S, Jafarov F, Abacar KY, Kutluğ Ağaçkıran S, Sevik G, Aslan R, Alibaz Öner F, İnanç N, Atagündüz MP, Seçkin D, Özen Alahdab Y, Ergun T, Direskeneli H, Atuğ Ö. Ergenç İ, et al. Among authors: atug o. Turk J Gastroenterol. 2023 Feb;34(2):156-160. doi: 10.5152/tjg.2022.22196. Turk J Gastroenterol. 2023. PMID: 36445058 Free PMC article.
Improvement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkey.
Toruner M, Basaranoglu M, Atug O, Senturk O, Akyuz F, Cekic C, Over Hamzaoglu H, Tekin F, Sezgin O, Akpinar H, Celik AF, Tezel A, Gokturk HS, Kav T. Toruner M, et al. Among authors: atug o. Turk J Gastroenterol. 2022 May;33(5):406-413. doi: 10.5152/tjg.2022.21868. Turk J Gastroenterol. 2022. PMID: 35678798 Free article.
44 results